The Foreign Corrupt Practices Act: Risk-Management and Compliance Strategies For Life Sciences and Pharmaceutical Companies

Just past its 30th birthday, the Foreign Corrupt Practices Act of 1977 (the FCPA or the Act) today poses the greatest liability risks ever for U.S. firms and other covered entities pursuing business opportunities abroad. Chiefly, this risk arises due to the increased risk of prosecution by the U.S. government, the government’s increased appetite for large fines, and an increased risk of multiple prosecutions due to other countries having adopted FCPA-equivalent laws.

Read the complete article by clicking on the link below.